- This topic has 2 replies, 2 voices, and was last updated 7 years, 2 months ago by
.
-
Posts
-
From me as @keith
Rheumatology 2.0 is out! http://t.co/YHCaeSAI6a Stories via @jorroser @PhilipGardiner @keithtaylor
— Carlo V Caballero MD (@carvicab) September 7, 2014
If you follow the Rheumatology 2.0 link, my article is in the “HEALTH” section on the left. It’s a review of gout treatments.
There is currently moderate quality data supporting the efficacy and safety of allopurinol, febuxostat, benzbromarone, and probenecid in gout. Pegloticase, while efficacious, is associated with more withdrawals due to adverse events and infusion reactions. There is insufficient evidence currently with respect to the cost-effectiveness or the most optimal sequencing of urate-lowering therapy.
Interesting that benzbromarone was more effective than probenecid at lowering uric acid levels, yet it is unavailable in America.
Wow, that Rheumatology 2.0 magazine updates quickly. My link does not appear in the latest version. If you want to check out the science, please go to http://www.jrheum.org/content/supplements/92/33.abstract Urate-Lowering Therapy for the Management of Gout: A Summary of 2 Cochrane Reviews.
- You must be logged in to reply to this topic.